Stay updated on NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients Clinical Trial
Sign up to get notified when there's something new on the NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients Clinical Trial page.

Latest updates to the NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 is now displayed on the page. The government funding lapse notice and the earlier Revision: v3.4.1 text have been removed.SummaryDifference0.5%

- Check21 days agoChange DetectedSite-wide notice about a lapse in government funding and open status was added, and the page revision tag was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check28 days agoChange DetectedA glossary toggle was added; labels such as 'Last Update Submitted that Met QC Criteria' were capitalized, capitalization adjusted for 'No FEAR Act Data', and the revision reference updated to v3.4.0 from v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check35 days agoChange DetectedThe AMD topic and related MedlinePlus Genetics topics were removed from the page content. This reduces the page’s contextual references to AMD and associated resources.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page adds the topic 'Age-related macular degeneration', adds a related topic 'MedlinePlus Genetics', and updates the revision tag from v3.3.3 to v3.3.4.SummaryDifference0.3%

- Check49 days agoChange DetectedThe disease term 'Age-related macular degeneration' and the related topic 'MedlinePlus Genetics' were removed from the page's topics.SummaryDifference0.2%

Stay in the know with updates to NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients Clinical Trial page.